Hepatology: From Natural History to Therapeutics—Second Edition

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 321

Special Issue Editor

E-Mail Website
Guest Editor
IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
Interests: HCV; HBV; cirrhosis; HCC
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 1986, Prof. Jay Hoofnagle had not become the Digestive Diseases and Nutrition Division director at the NIDDK, NIH. However, he had already published pioneering work on Hepatitis B interferon treatment. In December 1986, his seminal article on a treatment with the recombinant human alpha interferon of chronic non-A non-B hepatitis—later called HCV hepatitis—began a new era in hepatitis C research and hepatology. Until then, it was believed that hepatitis C was untreatable, the natural history of viral hepatitis had not been completely elucidated, and diagnostic assays for hepatitis B and C had not been developed.

The availability of an antiviral treatment for chronic hepatitis attracted interest in liver diseases, and the eventual approval of using interferon for hepatitis B and C treatments was the driver for supporting research in the field.

What are the remaining issues in hepatology? Some of the remaining challenges researchers face are how a treatment based on oral direct-acting antivirals impacts HCV hepatitis outcomes; when the experimental compounds for hepatitis B and delta treatments will become available, and how they will be used; whether the diagnostics of HBV-related diseases will change now and how efforts to reach underserved populations will succeed, such as homeless people and those at high risk of HCV infection transmission.

This honorary issue, celebrating Prof. Jay Hoofnagle, collects a series of essays on liver disease pathogenesis and treatment, exploring how Prof. Hoofnagle’s action—including the most recent study on DILI—promoting liver disease research, training, and education have introduced global significant changes in the field of liver diseases.

Prof. Dr. Alessandra Mangia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HCV
  • HBV
  • cirrhosis
  • HCC

Related Special Issue

Published Papers

This special issue is now open for submission.
Back to TopTop